Cytochrome P-450 CYP2C9 Inducers (strong)

All categories
Name
Cytochrome P-450 CYP2C9 Inducers (strong)
Accession Number
DBCAT002637
Description

Not Available

Drugs
DrugDrug Description
DabrafenibA kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer.
Drugs & Drug Targets
DrugTargetType
DabrafenibCytochrome P450 3A4enzyme
DabrafenibCytochrome P450 2C8enzyme
DabrafenibP-glycoprotein 1transporter
DabrafenibATP-binding cassette sub-family G member 2transporter
DabrafenibSolute carrier organic anion transporter family member 1B1transporter
DabrafenibSolute carrier organic anion transporter family member 1B3transporter
DabrafenibSolute carrier family 22 member 6transporter
DabrafenibSolute carrier family 22 member 8transporter
DabrafenibSerine/threonine-protein kinase B-raftarget
DabrafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DabrafenibSerine/threonine-protein kinase SIK1target
DabrafenibSerine/threonine-protein kinase Nek11target
DabrafenibLIM domain kinase 1target
DabrafenibCytochrome P450 2B6enzyme
DabrafenibCytochrome P450 2C9enzyme
DabrafenibCytochrome P450 2C19enzyme
DabrafenibCytochrome P450 1A2enzyme
DabrafenibSerum albumincarrier
DabrafenibSolute carrier organic anion transporter family member 1A2transporter
DabrafenibSolute carrier family 22 member 2transporter
DabrafenibUDP-glucuronosyltransferase 1-1enzyme